Italy’s New EFS Guidelines:  A Game-Changer for MedTech Innovation in Europe  

20 Jun 2026

For years, Europe has been losing its edge in early-stage medical device trials. Let’s face it: trying to get a trial off the ground in the EU has become a regulatory headache. Between the fragmented rules across different member states, the skyrocketing compliance costs of the EU MDR, and the lack of a fast-track program like the US FDA’s “Breakthrough Device” designation, it’s no wonder innovators are looking elsewhere. First-in-human and early feasibility studies (EFS) are packing their bags and heading to the US, China, Japan, and South Korea—places that are actively rolling out the red carpet for medical innovation. But Italy is stepping up to change the narrative. And they aren’t just starting from scratch. 

The Road to a New Framework 

This shift didn’t happen overnight. Back in 2019, the Italian Ministry of Health launched a public call to determine whether the American-style EFS model could work under strict EU rules. 

That experiment led to the ARCTRAN study at Rome’s Policlinico Gemelli. It was a milestone: the first EFS formally conducted in Italy and the first in Europe under a fully MDR-compliant framework. When the team presented their findings to the Ministry in February 2024, they proved the concept worked. 

Following this success, the Ministry turned those lessons into official policy, publishing the National Guidelines on Early Feasibility Studies for Medical Devices in February 2025, alongside a practical “Analytical Code” to handle the legal and procedural heavy lifting. Together, they create a clear, efficient, and fully compliant pathway for international sponsors who want to bring their cutting-edge devices to Italy. 

What Exactly Is an Italian-Style EFS? 

In simple terms, an EFS is a clinical study done at the very beginning of a medical device’s life cycle—well before its design is set in stone. The goal isn’t to prove perfection, but to test early design concepts, see how the device functions, and gather initial safety data in a highly controlled environment. The feedback from these studies tells developers whether to keep pushing forward or head back to the drawing board. 

The key difference: This isn’t a traditional feasibility study or a large-scale trial where the design is locked. An EFS embraces “technological immaturity.” The device is expected to evolve based on what doctors experience in real time. Because of this, patient numbers are small—usually between 5 and 30 people—and enrollment happens in stages so the team can monitor safety and make tweaks along the way. 

Strict Compliance, No Shortcuts (Article 62) 

Italy isn’t looking for a loophole. Under the new guidelines, these studies fall squarely under Article 62 of the MDR, which regulates clinical investigations aimed at gathering data for official approval. 

Although the Italian framework streamlines authorization, sponsors must still demonstrate compliance with the fundamental requirements of MDR Chapter VI, including scientific validity, protection of subjects, benefit-risk justification, investigator qualifications, and appropriate monitoring arrangements. The accelerated pathway does not reduce the evidentiary expectations for patient safety or clinical oversight. 

Sponsors must still prepare a robust clinical investigation package in accordance with MDR Article 62 and Annex XV. This typically includes a Clinical Investigation Plan (CIP), Investigator’s Brochure, Clinical Evaluation Plan (CEP), Risk Management documentation aligned with ISO 14971, including benefit-risk evaluation and residual risk assessment, informed consent materials, and supporting technical documentation sufficient to demonstrate that the anticipated benefits justify the foreseeable risks associated with the investigation. 

By aligning with existing European guidance (specifically MDCG 2021-6), Italy is framing these “proof-of-concept” studies as a standard subset of pilot investigations. This gives sponsors a level of regulatory predictability that has been sorely missing in Europe. 

While some might be tempted to use Article 82 MDR, the authors of Italy’s Analytical Code warn that relying on national provisions risks creating a confusing patchwork of local rules, which hurts legal certainty and potentially compromises patient safety. By anchoring the process in Article 62, Italy has built a clean, reliable model that other EU countries can easily copy—no special regulatory exceptions required. 

Streamlining the Authorisation Process 

At the heart of this new framework is a fast-track approval process designed specifically for Early Feasibility Studies (EFS). 

Instead of the usual 60 to 90 days, the new pathway slashes the final authorization timeline down to a maximum of 30 to 45 days. Validation times are also getting a major haircut, dropping from the current 10-to-55-day window down to just 7 to 39 days (following the HEU-EFS project methodology). 

But speed isn’t the only benefit. Here is how the new framework lowers the barrier to entry: 

• Zero Authorization Fees: Italy is completely scrapping authorization fees for EFS. This removes a massive financial hurdle for startups and SMEs, bringing Italy in line with Europe’s best practices. 

• One Single Ethics Committee: By routing reviews through a single, centralized committee, the framework completely eliminates the redundant paperwork and administrative back-and-forth that usually drags down multi-site or complex studies. 

• Adaptive, Modular Approvals: Instead of resubmitting your entire dossier every time you make a tweak, protocols can now be structured in sequential modules. If you make a change, you only need targeted reauthorization for that specific module.The modular approach is particularly valuable for innovative technologies undergoing iterative development. Design refinements, software updates, usability improvements, or procedural modifications may be evaluated within predefined study modules, allowing sponsors to implement evidence-based improvements without repeatedly resubmitting an entirely new clinical investigation dossier, provided patient safety and study integrity remain adequately controlled 

• Proportionate Paperwork: No one should have to submit a pivotal-trial-sized dossier for an early-stage study. The new framework calibrates the required documentation to the actual phase of the study. This means a scaled-back Clinical Evaluation Plan, a simplified Risk Management Plan (under ISO 14971), and straightforward patient materials. 

• Clinical Governance and Good Clinical Practice: All Early Feasibility Studies conducted under the Italian framework must continue to comply with ISO 14155:2020 Good Clinical Practice requirements. Sponsors remain responsible for investigator qualification, study monitoring, adverse event reporting, data integrity, informed consent management, and protection of study participants throughout the clinical investigation lifecycle. These requirements ensure that accelerated authorization pathways do not compromise ethical standards or clinical oversight. 

• To support accelerated review timelines, sponsors are expected to submit complete and high-quality documentation at the outset. Incomplete submissions may result in validation delays or requests for additional information, potentially extending the overall authorization timeline. Early engagement with clinical sites, ethics committees, and regulatory advisors remains critical to maintaining expedited review schedules. 

The Bigger Picture: Four Pillars of Innovation 

The EFS pathway is actually just one part of a much grander plan. The Guidelines lay out four interconnected pillars designed to completely reshape how Italy handles medical innovation: 

1. The EFS Program: The foundation for early-stage testing. 

2. A Priority Review Pathway: A fast track for breakthrough devices. 

3. National HTA Integration: Direct alignment with the National Health Technology Assessment Programme (PNHTA) under EU Regulation 2021/2282. 

4. A Dedicated State Fund: A purchasing fund modeled after the pharmaceutical sector. This fund is designed to let Italian regions purchase cutting-edge medical devices outside of their standard spending caps. (While this end-to-end vision is incredibly promising, we are still waiting on some of the finer details regarding how this fund will be governed, scaled, and timed.) 

For devices designed to treat life-threatening or severely debilitating conditions—or those addressing a major unmet clinical need—manufacturers can request a dedicated regulatory track. Manufacturers seeking priority designation will likely need to demonstrate that the technology addresses a significant unmet clinical need or offers a substantial improvement over existing standards of care.The proposal is concrete: a maximum 120-day timeline, active involvement of Notified Bodies, technical coordination with the European Commission, and CE marking under the MDR for Class III and IIb devices. 

Moving in Lockstep with Europe (and Racing the Rest of the World) 

What makes Italy’s move so smart is that it isn’t happening in a vacuum. It perfectly anticipates where the rest of Europe is already heading. 

In December 2025, the European Commission tabled a legislative proposal to amend the MDR and IVDR (COM(2025)1023), which introduces dedicated pathways for breakthrough and orphan devices under a brand-new Article 52a. On top of that, the MDCG has already released its guidance on Breakthrough Technologies (MDCG 2025-9), and the EMA is launching a pilot program for expert panel advice on breakthrough devices in Q2 2026. Italy’s new framework aligns beautifully with this broader EU trajectory. 

And none of this is happening a moment too soon. Globally, the competition is fierce: 

• China’s NMPA reportedly cleared over 100 devices through its “Green Channel” in 2025, cutting clinical trial approval times down to just 30 working days. 

• South Korea’s “Market Immediate Entry” fast-track, launched in January 2026, aggressively compresses the time-to-clinical-use from 490 days down to just 80. 

• Japan continues to expand its highly successful Sakigake and conditional early approval programs. 

If Europe wants to stay in the game, fast-tracking breakthrough devices is no longer a luxury—it’s a survival strategy. And with this new framework, Italy is leading the charge. 

The European Connection 

Italy isn’t acting alone here. Its new framework is structurally linked to the HEU-EFS project (Harmonized Approach to Early Feasibility Studies for Medical Devices in the European Union). This is a Horizon Europe Innovative Health Initiative consortium, led by Italy and tasked by the European Commission with designing a unified EFS methodology for the entire EU. 

Because of this direct connection, Italy’s national guidelines perfectly mirror the HEU-EFS project in its processes, timelines, templates, and KPIs. In fact, the Clinical Investigation Plan template and checklist were built directly within this European framework. 

The HEU-EFS initiative is expected to serve as a foundation for broader European harmonization of Early Feasibility Study requirements. By aligning national procedures, templates, review methodologies, and performance indicators, the project seeks to reduce regulatory fragmentation and provide greater predictability for manufacturers conducting multinational clinical investigations across Europe. 

With the European Commission’s December 2025 proposal now aiming to write Breakthrough and Orphan Device pathways directly into the MDR, Italy is essentially piloting what could very well become the blueprint for the entire European Union. Of course, while this is a massive step toward harmonization, its ultimate success across Europe will depend on other member states matching Italy’s administrative speed and market incentives. 

What This Means for International Sponsors 

If you are a MedTech company planning your next early-stage clinical program in Europe, Italy has just put a highly competitive package on the table. Here is what you actually get: 

• A rock-solid legal foundation with no regulatory gray areas. 

• Rapid-fire approval in just 30 to 45 days, with absolutely zero filing fees. 

• Flexible, adaptive protocols that let you iterate on the go. 

• Direct access to world-class IRCCS (scientific research hospitals), university clinics, and medical centers with deep expertise in cutting-edge device trials. 

• Perfect alignment with upcoming EU-wide standards. 

Sponsors considering Italy as an entry point for European clinical investigations should establish a comprehensive regulatory strategy early in development. Key preparation activities include defining the clinical investigation objectives, establishing an ISO 14971-compliant risk management framework, identifying qualified clinical partners, developing a compliant Clinical Investigation Plan, and ensuring alignment with future MDR conformity assessment and reimbursement objectives. 

To make things even easier, the Analytical Code plans to introduce a mapped network of qualified clinical sites. International sponsors coming to Italy for the first time will be able to search for partners based on their specific therapeutic expertise, infrastructure, and past trial performance. 

The Bottom Line 

What makes these guidelines stand out isn’t just their ambition—it’s how thoroughly they’ve been thought through. 

By connecting the dots between early-stage EFS, priority reviews, HTA integration, and a dedicated purchasing fund, Italy has addressed the entire life cycle of a medical device, from the first clinical test to hospital procurement. 

The legal foundation is incredibly sturdy because it is built on Article 62, avoiding the messy national workarounds that often plague European trials. The practical tools are ready to go. And the timing is flawless: with the Commission’s MDR revision currently on the table and the MDCG breakthrough pilot launching this year, Italy has positioned itself as the logical reference model for the continent. 

Despite the accelerated framework, successful execution of an Early Feasibility Study still requires careful planning and cross-functional coordination. Regulatory, clinical, quality, risk management, and engineering teams must work together to ensure that evolving device designs remain appropriately documented, risk-controlled, and supported by objective clinical evidence throughout the study. Manufacturers that establish these foundations early will be best positioned to leverage Italy’s new pathway efficiently. 

In a fierce global race for early-stage clinical trials, Europe has desperately needed a country to step up and lead. Italy just did exactly that. 

Accelerating Innovation with Compliance Confidence 

Italy’s new Early Feasibility Study (EFS) guidelines mark a turning point for MedTech in Europe, offering startups and global sponsors a fast‑track, legally solid pathway to test breakthrough devices. By anchoring the framework in Article 62 MDR, streamlining approvals to 30–45 days, and eliminating authorization fees, Italy has positioned itself as the EU’s reference model for early‑stage trials. 

At TS Quality & Engineering, we help innovators seize this opportunity by aligning device development with ISO 14971 risk management, ISO 13485 quality systems, and MDR/IVDR compliance. Our expertise ensures that sponsors can move quickly without compromising patient safety or regulatory certainty. Whether you’re preparing an EFS, scaling toward CE marking, or navigating EU harmonization, we partner with you to turn compliance into a catalyst for innovation. 

Partner with TS Quality & Engineering to accelerate your MedTech journey in Europe — where speed, safety, and regulatory clarity converge.